Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 57Recruiting 15Terminated 10Active not recruiting 5Unknown 4Withdrawn 1Suspended 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Gemtuzumab × Clear all
NCT01548911 2018-07-02

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Wake Forest University Health Sciences

Phase 2 Withdrawn
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡